Genital Warts (HPV) in Indian Women: Treatment & Prevention

• Genital warts are caused by low-risk HPV types 6 and 11, which cause about 90% of visible warts but do not cause cancer.
• The cancer-causing types (mainly 16 and 18) are different and usually cause no visible warts, so keep cervical screening up to date separately.
• Diagnosis is usually a simple visual exam by an OB-GYN or dermatologist; treatment options include topical creams and clinic procedures.
• Treatment removes visible warts but does not instantly clear HPV, so recurrence in the first six months is common and not a treatment failure.
• The HPV vaccine (Cervavac or Gardasil) is the single most effective way to prevent genital warts and HPV-related cancers.
• A genital warts diagnosis is a medical issue, not a moral one; free, confidential care is available at NACO STI clinics.

Genital warts (medically, condyloma acuminata) are soft, skin-coloured or pinkish growths that appear on the moist skin and mucous membranes of the genital and anal area. They are caused by human papillomavirus, specifically the low-risk types 6 and 11, which together account for about 90% of all visible genital warts. The virus infects surface skin cells and makes them multiply, producing the classic cauliflower-like clusters or small flat bumps over weeks to months.

They are common. At any given time, roughly 1% of sexually active adults have visible warts, and lifetime exposure to some HPV type is far higher because the virus is widespread. The bumps are usually painless, sometimes itchy, and almost always more distressing emotionally than they are dangerous medically. They do not threaten fertility or general health, and most clear with treatment within a few months.

The key reassurance to hold from the start: genital warts are neither rare nor a sign of moral failing. They are a common skin manifestation of a common virus, and the right frame is medical management, not shame. For the wider picture of the virus behind them, see our guide to HPV types, symptoms and treatment.

There are more than 100 HPV types, broadly split into low-risk and high-risk groups. The low-risk types, mainly 6 and 11, cause visible genital warts but do not cause cancer. The high-risk types, mainly 16 and 18 (with smaller contributions from 31, 33, 45, 52 and 58), rarely cause visible warts but are responsible for almost all cervical cancer and significant shares of anal, vulvar, vaginal and throat cancers. The two groups are biologically and clinically distinct.

What this means for a woman with genital warts is simple: the warts themselves will not turn into cancer. Treating them removes the visible disease but does not change cancer risk either way. Cancer risk depends on whether she also carries a high-risk type, a separate question answered by a Pap smear and HPV testing of the cervix. Because both groups spread the same way, co-infection is common, so anyone with visible warts should keep cervical cancer screening current and understand the normal range of cervical changes across life.

The take-home: visible warts come from HPV 6 and 11, are not cancer and will not become cancer. The cancer-risk question is separate, is answered by screening, and is reduced by the HPV vaccine, which protects against both the high-risk and the wart-causing types.

Genital warts spread through skin-to-skin contact during vaginal, anal or oral sex with a partner who carries the wart-causing HPV. Penetration is not required; close genital skin contact is enough. The virus enters through tiny breaks in the skin that occur naturally during sex, then sets up infection in surface cells. The incubation period before warts appear ranges from a few weeks to over a year, which makes it hard to pinpoint exactly when or from whom the infection was acquired.

Condoms reduce but do not eliminate transmission. Wart-causing HPV can sit on skin not covered by a condom (the base of the penis, scrotum, vulva, perineum and anal area), so spread is still possible with consistent use. Research suggests condoms cut transmission meaningfully rather than near-completely, and they remain worth using because partial protection is real and they reduce other infections at the same time, as covered in our guide to how effective condoms are.

A person can also transmit HPV without ever having visible warts. The virus is often present on normal-looking skin, and many carriers never develop warts themselves. So a partner who has never had a visible wart can still pass on the infection, and the appearance of warts in one partner does not mean the other has been unfaithful. The virus may have been acquired years earlier and stayed latent until warts appeared. Genital warts are one of several sexually transmitted infections every woman should understand.

In women, genital warts usually appear as small, soft, pinkish or skin-coloured bumps on the vulva (the outer genital area). They may stay small and separate or cluster into the classic cauliflower-like patch. The texture is typically soft rather than hard, and the surface is often irregular or papillary rather than smooth. Common sites include the labia majora and minora, the area around the vaginal opening, the perineum (between vagina and anus), the anus and perianal skin, and inside the vagina or on the cervix, where they are visible only on a speculum exam.

Warts can also appear in the mouth and throat after oral sex with an infected partner, though this is less common. Most are painless, but they can itch, become irritated by clothing or hygiene products, or bleed if rubbed or scratched. Larger clusters may cause discomfort during sex. The classic cauliflower look is recognisable, but smaller early warts can resemble simple skin tags or flat bumps and are easily missed without close inspection.

Any new bump in the genital area that lasts more than a couple of weeks deserves an OB-GYN or dermatologist look. Self-diagnosis is unreliable because several other things, including skin tags, molluscum contagiosum, cysts and normal anatomical variants such as vulvar papillomatosis, can look similar. If you have itching without an obvious bump, our guide to an itchy vulva without discharge covers the wider list of causes.

In most cases, diagnosis is a clinical visual examination by an OB-GYN or dermatologist, and a confident eye-only diagnosis is usually enough for typical external warts. The doctor inspects the vulva, perineum and anal area under good lighting and adds a speculum examination to check the vaginal walls and cervix. The visit usually takes 10 to 15 minutes and is comfortable apart from the speculum step. Private OB-GYN consultations range from around 500 to 1,500, while NACO-supported STI clinics offer the assessment free and confidentially.

When the appearance is uncertain, the acetic acid test is a simple bedside aid: dilute white vinegar applied to the area turns wart tissue temporarily white (acetowhitening), which helps distinguish warts from normal skin. It is not specific enough to use alone but is useful alongside the visual exam. For lesions that look atypical, are unusually pigmented, large or ulcerated, or fail to respond to treatment, a biopsy under local anaesthesia (around 800 to 2,500) is sent for histopathology to rule out high-grade changes or malignancy.

Because cervical involvement is possible and co-infection with high-risk HPV is common, any woman with external warts should also have a Pap smear (around 300 to 1,500 in private labs, free in government programmes) and ideally an HPV test to assess the cervix separately; an abnormal result is worked up as described in our guide to an abnormal Pap smear and next steps. NACO STI clinic protocols routinely include free, confidential HIV testing with any STI workup because the infections share transmission routes and the result changes management; see HIV in Indian women and where to get STI testing in India.

Topical treatments are the gentlest first line for small or moderate external warts and are often combined with later procedures if needed. Imiquimod 5% cream (Imiquad and other Indian brands, around 400 to 800 per sachet pack) is a patient-applied immune-response modifier applied to the warts three times a week at bedtime, washed off after 6 to 10 hours, for up to 16 weeks. It works by prompting the local immune system to clear the virus and the warts. Mild redness and irritation are expected and tolerable; severe burning means pausing for a few days.

Podophyllotoxin (or the related podophyllin solution) is a plant-derived antimitotic applied directly to the warts to destroy abnormal cells. Podophyllin (10–25%) is clinician-applied because of its strength and washed off after one to four hours; it is available free at primary health centres and NACO STI clinics. Patient-applied podophyllotoxin 0.5% solution is used twice daily for three days, then four days off, for up to four cycles. Both forms work over four to six weeks and are not used in pregnancy.

Trichloroacetic acid (TCA) 80–90% is a chemical cauterant applied carefully to each wart by the doctor, with any spilled acid neutralised using sodium bicarbonate. Several weekly sessions are usually needed, at around 300 to 800 per session in private clinics. TCA is one of the few topical options considered safe in pregnancy. Across all topical options, the typical course runs four to six weeks before deciding whether the warts have cleared, partially responded, or should be switched to a procedure.

When topical treatment is not enough, when warts are large or numerous, or when faster clearance is preferred, procedural removal at an OB-GYN or dermatology clinic is the next step. Cryotherapy with liquid nitrogen freezes the wart and destroys the abnormal cells; applied by probe or spray, it takes a few minutes per wart, causes a brief sharp sting, and usually needs two to four sessions a week or two apart. Private clinics charge around 500 to 2,000 per session, and the technique is widely available in Indian dermatology and gynaecology practice.

Electrocautery uses a small electric current to burn off the warts under local anaesthesia, takes 10 to 20 minutes for a small to moderate area, and is typically a single session with a one- to two-week recovery, at around 1,500 to 4,000 in private clinics. Laser ablation (usually CO2 laser) vaporises warts precisely and is preferred for hard-to-reach areas, large clusters, vaginal or cervical warts, and recurrent disease that has not responded to other methods; it ranges from around 5,000 to 15,000 per session at major hospitals and dermatology chains.

Surgical excision under local or short general anaesthesia is reserved for very large warts, those needing tissue for biopsy, or cases where other methods have failed. The choice between cryotherapy, electrocautery, laser and excision depends on wart size and location, the doctor's available equipment, cost and pregnancy status, and is made together with the treating clinician. Many women need a combination of topical and procedural approaches over the full course.

Genital warts behave differently in pregnancy because of its immune and hormonal changes: they often grow faster, may become larger and more vascular, and can occasionally form bulky clusters that affect comfort or a planned vaginal delivery. The reassuring part is that most warts in pregnancy can still be managed, and the small risk of passing HPV to the baby during delivery (causing rare juvenile-onset recurrent respiratory papillomatosis) does not by itself require a caesarean. Vaginal delivery is appropriate for most women with genital warts unless the warts are large enough to physically obstruct the birth canal or bleed heavily.

Treatment in pregnancy uses only the safe options: trichloroacetic acid (TCA) applied in the clinic, cryotherapy, electrocautery and surgical excision under local anaesthesia. These are routinely used by OB-GYNs when wart removal is needed before delivery. Podophyllin, podophyllotoxin and imiquimod are avoided in pregnancy because of theoretical or proven risk to the baby; podophyllin in particular can cause fetal harm if absorbed and is contraindicated.

The OB will usually monitor warts through pregnancy and decide whether to treat before delivery based on size, location and bleeding. Many small warts are left alone because they often regress on their own in the weeks after delivery as hormones settle. Open conversation with your OB about the warts, the delivery plan and any new growth between visits is the right approach.

Partner involvement matters in two practical ways. First, a male partner should be examined for visible warts on the penis, scrotum, perianal area or mouth, and any visible warts treated, because untreated warts in one partner are a continued source of viral load to the other. Most men can be examined and treated by a dermatologist or urologist using the same options (cryotherapy, electrocautery, imiquimod, podophyllin). Second, both partners should understand that condoms reduce but do not eliminate transmission, that the virus can spread without visible warts, and that long-term mutual monogamy with a previously uninfected partner is the most effective behavioural reduction.

The HPV vaccine is the single most effective prevention tool. In India, two vaccines are available: Cervavac, the Indian-made quadrivalent vaccine from Serum Institute, protecting against HPV 6, 11, 16 and 18 at around 2,000 to 2,500 per dose; and Gardasil, the imported nine-valent vaccine, protecting against HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 at around 3,000 to 4,500 per dose. Both prevent the wart-causing types 6 and 11 as well as the main cancer-causing types, and are the cornerstone of HPV prevention.

The vaccine works best given before any HPV exposure, ideally before sexual debut. The Indian schedule recommends it from age 9, with two doses (six months apart) for under-15s or three doses for older adolescents and adults. It is still worthwhile after exposure or even after a wart diagnosis, because protection against strains not yet acquired is still gained. For full details, see our guide to the HPV vaccine in India: Cervavac vs Gardasil.

Recurrence after successful clearance is common and expected rather than a sign of treatment failure. Between 30% and 70% of women have a recurrence within six months of finishing treatment, because clearing visible warts does not always clear the underlying HPV from surrounding skin. The immune system keeps working on the latent virus in the background, and most women eventually clear the infection completely, with around 90% reaching clearance within two years.

Recurrent warts are managed with the same options as the first episode, usually a combination of topical imiquimod or podophyllin plus procedural removal, and most respond as well as the first time. Recurrences that are persistent, multiple or unusually aggressive deserve a closer look. A clinician experienced in HPV disease may consider extended imiquimod courses and may request HIV testing, because immunosuppression is a known driver of treatment-resistant warts.

The long-term outlook is good. The infection clears in the great majority within one to two years, recurrences become less frequent over time, and the warts do not progress to cancer. Any cancer risk from a concurrent high-risk HPV infection is handled separately through routine cervical screening; if a screen is abnormal, the next step is often a Colposcopy in India: Why It's Needed, How It's Done, and What It Costs, and in rare cases persistent high-risk infection on the vulva is followed for vulvar and vaginal cancer.

• Any new bump, growth or cluster in the genital, anal or surrounding area that lasts more than two weeks.
• A wart that bleeds, ulcerates, grows quickly, is unusually firm, dark or fixed, or causes pain.
• Warts during pregnancy, or new genital growths if you are planning a vaginal delivery.
• Warts that do not clear after a full course of treatment, or that keep coming back aggressively.
• Any genital itching, abnormal discharge, sores or pain alongside the bumps, which may signal a co-existing infection.
• A wart diagnosis without a recent Pap smear or HPV test, so cervical health can be checked separately.

• World Health Organization — Human papillomavirus and cancer
• CDC — Genital HPV Infection Fact Sheet
• National AIDS Control Organisation (NACO), India — National Guidelines on STI/RTI Management
• NHS — Genital warts
• ACOG — Human Papillomavirus (HPV) Vaccination